The absence of these correlations suggests that the IL-6 does not effectively reflects liver function as plasmatic marker, and cannot replace or be associated with a biopsy to assess NAFLD progression clinically. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.